Immune augmentation by an orally active peptide following transplantation for lymphoma (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Immune augmentation by an orally active peptide following transplantation for lymphoma (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 37:A3340 1996. Unique Identifier : AIDSLINE ICDB/97633340
Talmadge J; Ino K; Walker S; Heinmann D; Bierman P; Univ. of Nebraska Medical Center, Omaha, NE 68198

Abstract: Bestatin [(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine], is an orally-active immune modulator which binds to CD13. Bestatin (Ubenimex) augments immune function, significantly prolongs survival in acute myelogenous leukemia and induces a graft-versus-host effect in allogenic bone marrow transplant (BMT) patients who did not develop chronic graft-versus-host disease. To determine the optimal immunomodulating dose, a phase Ib trial was conducted with 60 non-Hodgkin's and Hodgkin's lymphoma patients who received 10-180 mg bestatin po daily for 60 days. Patients received BMT or peripheral stem cell transplantation and were randomized to either drug or no drug. Therapy was initiated when the absolute neutrophil count was greater than 250/mm3. Bestatin significantly increased the pokeweed mitogen response and the frequency of B-cells in the peripheral blood as measured by IgM+ and CD19+ cells. Bestatin also increased the CD4:CD8 cell ratio and the frequency of CD45RA+ cells. There was also an increase in NK function in BMT patients, total CD56+ and CD3-, CD8-, CD56+ cells. The phytohemagglutinin (measure of T-cell activity) response was increased, as was monocyte function as measured by serum neopterin and colony stimulating levels, and CD6 and HLADr expression. Optimal activity was observed at 90 mg/day (tid 30 mg tablets) in both the BMT and PSCT trials.

Keywords: Administration, Oral Antigens, CD/IMMUNOLOGY B-Lymphocytes/DRUG EFFECTS/IMMUNOLOGY *Bone Marrow Transplantation CD4-CD8 Ratio/DRUG EFFECTS *Hematopoietic Stem Cell Transplantation Hodgkin's Disease/*DRUG THERAPY/IMMUNOLOGY/SURGERY Human Leucine/*ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE/ THERAPEUTIC USE Lymphoma, Non-Hodgkin's/*DRUG THERAPY/IMMUNOLOGY/SURGERY T-Lymphocytes/DRUG EFFECTS/IMMUNOLOGY ABSTRACT
970330
M9731540

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .